Hikma Pharmaceuticals, an Amman, Jordan-based pharmaceutical company, has invested $28 million in additional capacity for injectable products at its facility in Cherry Hill, New Jersey and an additional $8 million at its site in Terrugem, Portugal. The company plans to build a facility exclusively for injectable oncology products at its Portugal site. The company made the announcements as part of its second-quarter 2017 earnings release.

The firm plans to add: (1) an additional 70 million units to its liquid and vials capacity to bring the total to 550 million units; (2) 80 million units to its prefilled syringes capacity to bring the total to 100 million units; (3) and 13 million units to its infusion bags capacity to bring the total to 16 million units.

The expansion also includes an additional 120 square meters of yophilized product capacity to bring the total to 176 square meters.

The company reported first-half revenues of $895 million, of which $362 million was for injectables and expects injectables revenues of around $775 million by the end of 2017.

Source: Hikma Pharmaceuticals (Second-Quarter Earnings Release and Presentation) and Hikma Pharmaceuticals (Second-Quarter Earnings Webcast)